Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

C4 Therapeutics Inc (CCCC)

C4 Therapeutics Inc (CCCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 283,062
  • Shares Outstanding, K 70,589
  • Annual Sales, $ 20,760 K
  • Annual Income, $ -132,490 K
  • EBIT $ -119 M
  • EBITDA $ -121 M
  • 60-Month Beta 3.04
  • Price/Sales 13.77
  • Price/Cash Flow N/A
  • Price/Book 1.21

Options Overview Details

View History
  • Implied Volatility 159.41% ( +40.82%)
  • Historical Volatility 85.11%
  • IV Percentile 69%
  • IV Rank 38.45%
  • IV High 401.71% on 02/05/24
  • IV Low 8.04% on 07/12/24
  • Put/Call Vol Ratio 3.33
  • Today's Volume 13
  • Volume Avg (30-Day) 262
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 10,430
  • Open Int (30-Day) 11,337

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.45
  • Number of Estimates 5
  • High Estimate -0.32
  • Low Estimate -0.59
  • Prior Year -0.68
  • Growth Rate Est. (year over year) +33.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.84 +4.43%
on 11/20/24
6.52 -38.50%
on 11/04/24
-2.20 (-35.43%)
since 10/22/24
3-Month
3.84 +4.43%
on 11/20/24
7.22 -44.46%
on 09/13/24
-2.05 (-33.83%)
since 08/22/24
52-Week
1.06 +278.30%
on 12/06/23
11.88 -66.25%
on 03/04/24
+2.49 (+163.82%)
since 11/22/23

Most Recent Stories

More News
C4 Therapeutics Appoints Steve Hoerter to Board of Directors to Strengthen Oncology Expertise

C4 Therapeutics appoints Steve Hoerter to its Board, enhancing oncology expertise to advance targeted protein degradation innovations.Quiver AI SummaryC4 Therapeutics, Inc. has announced the appointment...

CCCC : 4.01 (unch)
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

CCCC : 4.01 (unch)
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial

CCCC : 4.01 (unch)
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting

CCCC : 4.01 (unch)
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

CCCC : 4.01 (unch)
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CCCC : 4.01 (unch)
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

CCCC : 4.01 (unch)
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

CCCC : 4.01 (unch)
Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults

/CNW/ -- USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale...

ONCY : 1.0200 (+4.08%)
TCRX : 3.94 (-4.37%)
BMY : 58.25 (+0.03%)
PDSB : 2.21 (+0.23%)
CCCC : 4.01 (unch)
ONC.TO : 1.37 (-2.14%)
Global Efforts Intensify to Address Surging Young Adult Colorectal and Anal Cancer Rates

USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale Medicine. As well, there are now alarming reports around...

ONCY : 1.0200 (+4.08%)
ONC.TO : 1.37 (-2.14%)
TCRX : 3.94 (-4.37%)
BMY : 58.25 (+0.03%)
PDSB : 2.21 (+0.23%)
CCCC : 4.01 (unch)

Business Summary

C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. C4 Therapeutics...

See More

Key Turning Points

3rd Resistance Point 4.69
2nd Resistance Point 4.50
1st Resistance Point 4.26
Last Price 4.01
1st Support Level 3.83
2nd Support Level 3.64
3rd Support Level 3.40

See More

52-Week High 11.88
Fibonacci 61.8% 7.75
Fibonacci 50% 6.47
Fibonacci 38.2% 5.19
Last Price 4.01
52-Week Low 1.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar